HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Biodistribution of antisense nanoparticles in mammary carcinoma rat model.

Abstract
Efficient and specific delivery of antisenses (ASs) and protection of the sequences from degradation are critical factors for effective therapy. Sustained release nanoparticles (NP) offer increased resistance to nuclease degradation, increased amounts of AS uptake, and the possibility of control in dosing and sustained duration of AS administration. The biodegradable and biocompatible poly(D,L-lactic-co-glycolic acid) copolymer (PLGA) was utilized to encapsulate AS directed against osteopontin (OPN), which is a promising therapeutic target in mammary carcinoma. Whole body biodistribution of OPN AS NP was evaluated in comparison to naked AS, in intact and mammary carcinoma metastasis model bearing rats. Naked and NP encapsulated AS exhibited different biodistribution profiles. AS NP, in contrast to naked AS, tended to accumulate mostly in the spleen, liver, and at the tumor inoculation site. Drug levels in intact organs were negligible. The elimination of naked AS was faster, due to rapid degradation of the unprotected sequence. It is concluded that AS NP protect the AS from degradation, provide efficient AS delivery to the tumor tissue, and minimize AS accumulation in intact organs due to the AS sustained release profile as well as the favorable NP physicochemical properties.
AuthorsVictoria Elazar, Hassan Adwan, Keren Rohekar, Michael Zepp, Rinat Lifshitz-Shovali, Martin R Berger, Gershon Golomb
JournalDrug delivery (Drug Deliv) Vol. 17 Issue 6 Pg. 408-18 (Aug 2010) ISSN: 1521-0464 [Electronic] England
PMID20429847 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Antisense Elements (Genetics)
  • Delayed-Action Preparations
  • Drug Carriers
  • Osteopontin
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Lactic Acid
Topics
  • Animals
  • Antineoplastic Agents (analysis, blood, pharmacokinetics, urine)
  • Antisense Elements (Genetics) (analysis, blood, pharmacokinetics, urine)
  • Bone Neoplasms (blood, drug therapy, secondary, urine)
  • Carcinoma (blood, drug therapy, secondary, urine)
  • Cell Line, Tumor
  • Delayed-Action Preparations (analysis, chemistry, pharmacokinetics, therapeutic use)
  • Drug Carriers (analysis, pharmacokinetics)
  • Drug Delivery Systems
  • Female
  • Humans
  • Lactic Acid (analysis, chemistry, therapeutic use)
  • Male
  • Mammary Neoplasms, Experimental (blood, drug therapy, urine)
  • Nanoparticles (analysis, chemistry, therapeutic use)
  • Osteopontin (genetics)
  • Particle Size
  • Polyglycolic Acid (analysis, chemistry, therapeutic use)
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Rats
  • Rats, Nude
  • Tissue Distribution
  • Xenograft Model Antitumor Assays (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: